Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose
Por:
Jabbour, E, Advani, A, Gokbuget, N, Ribera, J, Stock, W, Cassaday, R, DeAngelo, DJ, Dorman, S, Williams, S, Zhang, F, Vandendries, E and Kantarjian, H
Publicada:
1 sep 2025
Resumen:
Filiaciones:
Jabbour, E:
Univ Texas MD Anderson Canc Ctr, Houston, TX USA
Advani, A:
Cleveland Clin, Cleveland, OH USA
Gokbuget, N:
Goethe Univ Hosp, Frankfurt, Germany
:
Inst Catala Oncol, Barcelona, Spain
Josep Carreras Res Inst, Barcelona, Spain
Stock, W:
Univ Chicago, Chicago, IL USA
Cassaday, R:
Univ Washington, Sch Med, Seattle, WA USA
Fred Hutchinson Canc Ctr, Seattle, WA USA
DeAngelo, DJ:
Dana Farber Canc Inst, Boston, MA USA
Dorman, S:
Pfizer Inc, St Catharines, ON, Canada
Williams, S:
Pfizer Inc, Columbus, OH USA
Zhang, F:
Pfizer Inc, San Diego, CA USA
Vandendries, E:
Pfizer Inc, Cambridge, MA USA
Kantarjian, H:
Univ Texas MD Anderson Canc Ctr, Houston, TX USA
|